Cargando…

Phase I Clinical Trial of Everolimus Combined with Trimodality Therapy in Patients with Muscle-Invasive Bladder Cancer

Background: Local control following trimodality therapy (TMT) for muscle-invasive bladder cancer (MIBC) requires further optimization. Objective: Evaluating the biologic endpoint, feasibility, and toxicity of integrating everolimus to TMT in patients with MIBC. Methods: This was a phase I trial in p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bachir, Bassel G., Souhami, Luis, Mansure, Jose João, Cury, Fabio, Vanhuyse, Marie, Brimo, Fadi, Aprikian, Armen G., Tanguay, Simon, Sturgeon, Jeremy, Kassouf, Wassim
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	IOS Press 2017
Materias:	Research Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5409045/ https://www.ncbi.nlm.nih.gov/pubmed/28516155 http://dx.doi.org/10.3233/BLC-160090

Ejemplares similares

Role of Serum Lymphocyte-derived Biomarkers in Nonmetastatic Muscle-invasive Bladder Cancer Patients Treated with Trimodal Therapy
por: Kool, Ronald, et al.
Publicado: (2021)

Aldehyde dehydrogenase 1 expression in primary and metastatic renal cell carcinoma: an immunohistochemistry study
por: Abourbih, Samuel, et al.
Publicado: (2013)

Impact of Programmed Death-ligand 1 Expression on Oncological Outcomes in Patients with Muscle-invasive Bladder Cancer Treated with Radiation-based Therapy
por: Marcq, Gautier, et al.
Publicado: (2022)

Evaluation of RNA-binding motif protein 3 expression in urothelial carcinoma of the bladder: an immunohistochemical study
por: Florianova, Livia, et al.
Publicado: (2015)

Improving ultrasound-based prostate volume estimation
por: Aprikian, Saro, et al.
Publicado: (2019)

Changes in the outcome of prostate biopsies after preventive task force recommendation against prostate-specific antigen screening
por: Zakaria, Ahmed S., et al.
Publicado: (2018)

Retroperitoneal lymph node dissection for residual masses after chemotherapy in nonseminomatous germ cell testicular tumor
por: Luz, Murilo A, et al.
Publicado: (2010)

Combining mTOR Inhibition with Radiation Improves Antitumor Activity in Bladder Cancer Cells In Vitro and In Vivo: A Novel Strategy for Treatment
por: Nassim, Roland, et al.
Publicado: (2013)

Feasibility and Impact of Immunohistochemistry-based Molecular Subtyping for Muscle-invasive Bladder Cancer in Patients Treated with Radiation-based Therapy
por: Hesswani, Charles, et al.
Publicado: (2023)

Chronic prednisone, metformin, and nonsteroidal anti-inflammatory drug use and clinical outcome in a cohort of bladder cancer patients undergoing radical cystectomy in Québec, Canada
por: Wissing, Michel D., et al.
Publicado: (2023)

Bladder-sparing protocols in the treatment of muscle-invasive bladder cancer
por: Tholomier, Côme, et al.
Publicado: (2020)

Role of neutrophil extracellular traps in radiation resistance of invasive bladder cancer
por: Shinde-Jadhav, Surashri, et al.
Publicado: (2021)

Trimodality Therapy for Bladder Preservation in the Elderly Population with Invasive Bladder Cancer
por: Turgeon, Guy-Anne, et al.
Publicado: (2014)

Drug costs in the management of metastatic castration-resistant prostate cancer in Canada
por: Dragomir, Alice, et al.
Publicado: (2014)

Combined radiotherapy and immunotherapy in urothelial bladder cancer: harnessing the full potential of the anti-tumor immune response
por: Daro-Faye, Mame, et al.
Publicado: (2020)

Health-care services utilization and costs associated with radical cystectomy for bladder cancer: a descriptive population-based study in the province of Quebec, Canada
por: Santos, Fabiano, et al.
Publicado: (2015)

Presence of lymphocytic infiltrate cytotoxic T lymphocyte CD3(+), CD8(+), and immunoscore as prognostic marker in patients after radical cystectomy
por: Yu, Alice, et al.
Publicado: (2018)

A Novel Mechanism of PPAR Gamma Induction via EGFR Signalling Constitutes Rational for Combination Therapy in Bladder Cancer
por: Mansure, Jose Joao, et al.
Publicado: (2013)

Correction: A Novel Mechanism of PPAR Gamma Induction via EGFR Signalling Constitutes Rational for Combination Therapy in Bladder Cancer
por: Mansure, Jose Joao, et al.
Publicado: (2013)

The immune mediated role of extracellular HMGB1 in a heterotopic model of bladder cancer radioresistance
por: Ayoub, Mina, et al.
Publicado: (2019)

PTEN genomic deletion predicts prostate cancer recurrence and is associated with low AR expression and transcriptional activity
por: Choucair, Khalil, et al.
Publicado: (2012)

Relationship between initial PSA density with future PSA kinetics and repeat biopsies in men with prostate cancer on active surveillance
por: Kotb, A F, et al.
Publicado: (2011)

Trimodality Treatment for Muscle-Invasive Bladder Cancer: An Institutional Experience
por: Polineni, Praneet, et al.
Publicado: (2021)

Single Institutional Experience of Bladder-Preserving Trimodality Treatment for Muscle-Invasive Bladder Cancer
por: Joung, Jae Young, et al.
Publicado: (2008)

The Role of Transurethral Resection in Trimodal Therapy for Muscle-Invasive Bladder Cancer
por: Russell, Christopher M., et al.
Publicado: (2016)

Radical Cystectomy is the best choice for most patients with muscle-invasive bladder cancer? Opinion: Yes
por: Monteiro, Leonardo L., et al.
Publicado: (2017)

Early detection of clinically significant prostate cancer at diagnosis: a prospective study using a novel panel of TMPRSS2:ETS fusion gene markers
por: Chan, Sam W., et al.
Publicado: (2013)

Plasmacytoid urothelial carcinoma of the bladder: a case report
por: Aldousari, Saad, et al.
Publicado: (2009)

Conservative treatment of invasive bladder cancer
por: Rene, N.J., et al.
Publicado: (2009)

Outcomes for Muscle-invasive Bladder Cancer with Radical Cystectomy or Trimodal Therapy in US Veterans
por: Kumar, Abhishek, et al.
Publicado: (2021)

Trimodal Therapy Using an MR–guided Radiation Therapy Partial Bladder Tumor Boost in Muscle Invasive Bladder Cancer
por: Liveringhouse, Casey, et al.
Publicado: (2023)

Cell‐by‐cell quantification of the androgen receptor in benign and malignant prostate leads to a better understanding of changes linked to cancer initiation and progression
por: Derderian, Seta, et al.
Publicado: (2023)

Clinical Management and Burden of Prostate Cancer: A Markov Monte Carlo Model
por: Sanyal, Chiranjeev, et al.
Publicado: (2014)

Trimodal Therapy vs. Radical Cystectomy for Muscle-Invasive Bladder Cancer: A Meta-Analysis
por: Ding, Hui, et al.
Publicado: (2020)

Comparison between standard and reduced volume radiotherapy in bladder preservation trimodality protocol for muscle-invasive bladder cancer patients
por: Arafat, Waleed, et al.
Publicado: (2016)

Endoclips as novel fiducial markers in trimodality bladder-preserving therapy of muscle-invasive bladder carcinoma: feasibility and patient outcomes
por: Shahbaz, Muhammad, et al.
Publicado: (2020)

Bipolar disorder: Trimodal age‐at‐onset distribution
por: Bolton, Sorcha, et al.
Publicado: (2020)

Conditional survival of trimodal therapy for nonmetastatic muscle‐invasive bladder cancer: A SEER database analysis
por: Shangguan, Wentai, et al.
Publicado: (2022)

Analysis of MRE11 and Mortality Among Adults With Muscle-Invasive Bladder Cancer Managed With Trimodality Therapy
por: Magliocco, Anthony M., et al.
Publicado: (2022)

Trimodality Therapy in which Concurrent Chemoradiation with Concomitant Boost in Muscle Invasive TCC Urinary Bladder Cancer
por: Mohammed, Ayatallah Ali Youssief, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ilcn9be9hsk3125u159n5omjd2